 |
|
|
| |
Six Weeks of an NS5A Inhibitor (GS-5885) and a Protease Inhibitor (GS-9451) Plus Peginterferon+Ribavirin Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment-Naïve Hepatitis C Virus Patients: Interim Results of a Prospective, Randomized Trial
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Alexander Thompson1, Mitchell Shiffman2, Lorenzo Rossaro3, Reem Ghalib4, Steve Han5, Kimberly L. Beavers6, Stephen Pianko7, Lin He8, Xiaoru Wu8, Nikki Flores8,
Phil S. Pang8, Stephen Rossi8, John McHutchison8, Andrew J. Muir9, Sam Lee10, Jacob George11
1Saint Vincents Hospital, Melbourne, VIC, Australia; 2Liver Institute of Virginia, Newport News, VA, United States; 3University of California-Davis Medical Center, Sacramento, CA, United States; 4North Texas Research Institute, Arlington, TX, United States; 5West Los Angeles VAHCS, Los Angeles, CA, United States; 6Asheville Gastroenterology Associates, Asheville, NC, United States; 7Monash University, Melbourne, VIC, Australia; 8Gilead Sciences, Foster City, CA, United States; 9Duke Clinical Research Institute, Durham, NC, United States; 10University of Calgary, Calgary, AB, Canada; 11University of Sydney, Sydney, NSW, Australia
|
| |
|
|
|
|
|
